Response rate of regiment carboplatin plus etoposide for non-small cell lung cancer is inferior than regiment used new agent as paclitaxel, docetaxel or gemcitabine. On the other hand, the combination response of chemoradiotherapy could efficacy for non-small cell lunf cancer However, there is still controvers about the toxixities if full dosed chemotheapy is used in concurrent chemoradiotherap…